Pravastatin: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Pravastatin. Educational only — not medical advice.

Reported adverse reactions

ReactionHighest frequency reported*
Arthralgia)6%
Dyspepsia/heartburn3.7%
Angina pectoris3.4%
Fatigue3.4%
Chest pain2.6%
Abdominal pain2.5%
Rash2.2%
Dizziness2.2%
Muscle cramp2%
Headache1.9%
Nausea/vomiting1.6%
Dyspnea1.6%
Vision, diplopia)1.6%
Myalgia1.4%
Constipation1.3%
Upper respiratory infection1.3%
Flatulence1.2%
Anxiety/nervousness1.2%
Sleep disturbance1%
Depression1%

*Highest percentage across placebo-controlled trial tables summarized in current labeling.

Labeled uses

Therapy with pravastatin sodium tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. Primary Prevention of Coronary EventsIn hypercholesterolemic patients without clinically evident coronary heart disease, pravastatin sodium tablets are indicated to: - Reduce the risk of myocardial infarction - Reduce the risk of undergoing myocardial revascularization procedures - Reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes HyperlipidemiaPravastatin sodium tablets are indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb).6 Pravastatin sodium tablets are indicated as adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson Type IV). Pravastatin sodium tablets are indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not …

Source: FDA labeling via NIH DailyMed (set a5ca8004…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.